Metraipolis › archive › dc_d4e0c8494d3b

Post-marketing safety signal profile of mavacamten in the FDA adverse event reporting system (FAERS): a disproportionality analysis — Europe PMC PMID:42780356

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42780356
DOI
10.3389/fphar.2026.1906371
License (as archived)
solo-consultazione
Archived
2026-10-06T11:27:17.114Z
SHA-256 of the archived text
f6a25ce9b60a605a19a08a9f67d51b297709566b920da3154477ba772d1aff2b
Stable URL of this page
https://metraipolis.com/documento/dc_d4e0c8494d3b

How to cite

Post-marketing safety signal profile of mavacamten in the FDA adverse event reporting system (FAERS): a disproportionality analysis — Europe PMC PMID:42780356 — Europe PMC (en), https://europepmc.org/article/MED/42780356 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d4e0c8494d3b (Metraipolis archive dc_d4e0c8494d3b, sha256 f6a25ce9b60a605a19a08a9f67d51b297709566b920da3154477ba772d1aff2b)
BibTeX
@misc{dcd4e0c8494d3b,
  title = {Post-marketing safety signal profile of mavacamten in the FDA adverse event reporting system (FAERS): a disproportionality analysis — Europe PMC PMID:42780356},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42780356},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d4e0c8494d3b; sha256 f6a25ce9b60a605a19a08a9f67d51b297709566b920da3154477ba772d1aff2b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42780356. Agents can read the archived copy with the MCP tool read_document.